Liv.52 in alcoholic liver disease

A prospective, controlled trial

H. A. De Silva, P. A M Saparamadu, M. I. Thabrew, A. Pathmeswaran, M. M D Fonseka, H. J. De Silva

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Liv.52, a hepatoprotective agent of herbal origin, is used empirically for the treatment of alcoholic liver disease in Sri Lanka. We conducted a controlled trial to assess the efficacy of Liv.52 in patients with alcoholic liver disease. Patients with evidence of alcoholic liver disease attending outpatient clinics were included in a prospective, double blind, randomized, placebo controlled trial. During the trial period, 80 patients who fulfilled inclusion criteria were randomly assigned Liv.52 (cases; n=40) or placebo (controls) the recommended dose of three capsules twice daily for 6 months. All patients underwent clinical examination (for which a clinical score was computed), and laboratory investigations for routine blood chemistry and liver function before commencement of therapy (baseline). Thereafter, clinical assessments were done monthly for 6 months, while laboratory investigations were done after 1 and 6 months of therapy. There was no significant difference in the age composition, alcohol intake and baseline liver function between the two groups. The two-sample t-test was used to analyze data obtained after 1 and 6 months of therapy against baseline values. There was no significant difference in clinical outcome and liver chemistry between the two groups at any time point. There were no reports of adverse effects attributable to the drug. Our results suggest that Liv.52 may not be useful in the management of patients with alcohol induced liver disease.

Original languageEnglish
Pages (from-to)47-50
Number of pages4
JournalJournal of Ethnopharmacology
Volume84
Issue number1
DOIs
Publication statusPublished - Jan 1 2003

Fingerprint

Alcoholic Liver Diseases
Liver
Placebos
Alcohols
Sri Lanka
Therapeutics
Ambulatory Care Facilities
Capsules
Liver Diseases
Randomized Controlled Trials
Pharmaceutical Preparations

Keywords

  • Alcohol
  • Herbal
  • Liv.52

ASJC Scopus subject areas

  • Pharmacology

Cite this

De Silva, H. A., Saparamadu, P. A. M., Thabrew, M. I., Pathmeswaran, A., Fonseka, M. M. D., & De Silva, H. J. (2003). Liv.52 in alcoholic liver disease: A prospective, controlled trial. Journal of Ethnopharmacology, 84(1), 47-50. https://doi.org/10.1016/S0378-8741(02)00263-5

Liv.52 in alcoholic liver disease : A prospective, controlled trial. / De Silva, H. A.; Saparamadu, P. A M; Thabrew, M. I.; Pathmeswaran, A.; Fonseka, M. M D; De Silva, H. J.

In: Journal of Ethnopharmacology, Vol. 84, No. 1, 01.01.2003, p. 47-50.

Research output: Contribution to journalArticle

De Silva, HA, Saparamadu, PAM, Thabrew, MI, Pathmeswaran, A, Fonseka, MMD & De Silva, HJ 2003, 'Liv.52 in alcoholic liver disease: A prospective, controlled trial', Journal of Ethnopharmacology, vol. 84, no. 1, pp. 47-50. https://doi.org/10.1016/S0378-8741(02)00263-5
De Silva, H. A. ; Saparamadu, P. A M ; Thabrew, M. I. ; Pathmeswaran, A. ; Fonseka, M. M D ; De Silva, H. J. / Liv.52 in alcoholic liver disease : A prospective, controlled trial. In: Journal of Ethnopharmacology. 2003 ; Vol. 84, No. 1. pp. 47-50.
@article{cc31c76ff8534b309ee46590632f39bb,
title = "Liv.52 in alcoholic liver disease: A prospective, controlled trial",
abstract = "Liv.52, a hepatoprotective agent of herbal origin, is used empirically for the treatment of alcoholic liver disease in Sri Lanka. We conducted a controlled trial to assess the efficacy of Liv.52 in patients with alcoholic liver disease. Patients with evidence of alcoholic liver disease attending outpatient clinics were included in a prospective, double blind, randomized, placebo controlled trial. During the trial period, 80 patients who fulfilled inclusion criteria were randomly assigned Liv.52 (cases; n=40) or placebo (controls) the recommended dose of three capsules twice daily for 6 months. All patients underwent clinical examination (for which a clinical score was computed), and laboratory investigations for routine blood chemistry and liver function before commencement of therapy (baseline). Thereafter, clinical assessments were done monthly for 6 months, while laboratory investigations were done after 1 and 6 months of therapy. There was no significant difference in the age composition, alcohol intake and baseline liver function between the two groups. The two-sample t-test was used to analyze data obtained after 1 and 6 months of therapy against baseline values. There was no significant difference in clinical outcome and liver chemistry between the two groups at any time point. There were no reports of adverse effects attributable to the drug. Our results suggest that Liv.52 may not be useful in the management of patients with alcohol induced liver disease.",
keywords = "Alcohol, Herbal, Liv.52",
author = "{De Silva}, {H. A.} and Saparamadu, {P. A M} and Thabrew, {M. I.} and A. Pathmeswaran and Fonseka, {M. M D} and {De Silva}, {H. J.}",
year = "2003",
month = "1",
day = "1",
doi = "10.1016/S0378-8741(02)00263-5",
language = "English",
volume = "84",
pages = "47--50",
journal = "Journal of Ethnopharmacology",
issn = "0378-8741",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

TY - JOUR

T1 - Liv.52 in alcoholic liver disease

T2 - A prospective, controlled trial

AU - De Silva, H. A.

AU - Saparamadu, P. A M

AU - Thabrew, M. I.

AU - Pathmeswaran, A.

AU - Fonseka, M. M D

AU - De Silva, H. J.

PY - 2003/1/1

Y1 - 2003/1/1

N2 - Liv.52, a hepatoprotective agent of herbal origin, is used empirically for the treatment of alcoholic liver disease in Sri Lanka. We conducted a controlled trial to assess the efficacy of Liv.52 in patients with alcoholic liver disease. Patients with evidence of alcoholic liver disease attending outpatient clinics were included in a prospective, double blind, randomized, placebo controlled trial. During the trial period, 80 patients who fulfilled inclusion criteria were randomly assigned Liv.52 (cases; n=40) or placebo (controls) the recommended dose of three capsules twice daily for 6 months. All patients underwent clinical examination (for which a clinical score was computed), and laboratory investigations for routine blood chemistry and liver function before commencement of therapy (baseline). Thereafter, clinical assessments were done monthly for 6 months, while laboratory investigations were done after 1 and 6 months of therapy. There was no significant difference in the age composition, alcohol intake and baseline liver function between the two groups. The two-sample t-test was used to analyze data obtained after 1 and 6 months of therapy against baseline values. There was no significant difference in clinical outcome and liver chemistry between the two groups at any time point. There were no reports of adverse effects attributable to the drug. Our results suggest that Liv.52 may not be useful in the management of patients with alcohol induced liver disease.

AB - Liv.52, a hepatoprotective agent of herbal origin, is used empirically for the treatment of alcoholic liver disease in Sri Lanka. We conducted a controlled trial to assess the efficacy of Liv.52 in patients with alcoholic liver disease. Patients with evidence of alcoholic liver disease attending outpatient clinics were included in a prospective, double blind, randomized, placebo controlled trial. During the trial period, 80 patients who fulfilled inclusion criteria were randomly assigned Liv.52 (cases; n=40) or placebo (controls) the recommended dose of three capsules twice daily for 6 months. All patients underwent clinical examination (for which a clinical score was computed), and laboratory investigations for routine blood chemistry and liver function before commencement of therapy (baseline). Thereafter, clinical assessments were done monthly for 6 months, while laboratory investigations were done after 1 and 6 months of therapy. There was no significant difference in the age composition, alcohol intake and baseline liver function between the two groups. The two-sample t-test was used to analyze data obtained after 1 and 6 months of therapy against baseline values. There was no significant difference in clinical outcome and liver chemistry between the two groups at any time point. There were no reports of adverse effects attributable to the drug. Our results suggest that Liv.52 may not be useful in the management of patients with alcohol induced liver disease.

KW - Alcohol

KW - Herbal

KW - Liv.52

UR - http://www.scopus.com/inward/record.url?scp=0037219946&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037219946&partnerID=8YFLogxK

U2 - 10.1016/S0378-8741(02)00263-5

DO - 10.1016/S0378-8741(02)00263-5

M3 - Article

VL - 84

SP - 47

EP - 50

JO - Journal of Ethnopharmacology

JF - Journal of Ethnopharmacology

SN - 0378-8741

IS - 1

ER -